ID29150A - Penggunaan lactobacillus salivarius - Google Patents

Penggunaan lactobacillus salivarius

Info

Publication number
ID29150A
ID29150A IDW00200101531A ID20011531A ID29150A ID 29150 A ID29150 A ID 29150A ID W00200101531 A IDW00200101531 A ID W00200101531A ID 20011531 A ID20011531 A ID 20011531A ID 29150 A ID29150 A ID 29150A
Authority
ID
Indonesia
Prior art keywords
inflammatory activity
strain
lactobacillus salivarius
inflammatory
resected
Prior art date
Application number
IDW00200101531A
Other languages
English (en)
Indonesian (id)
Inventor
John C Collins
Grrald C O'sullivan
Liam O'mahony
Fergus Shanahan
Original Assignee
Entpr Ireland Cs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE990033A external-priority patent/IE990033A1/en
Application filed by Entpr Ireland Cs filed Critical Entpr Ireland Cs
Publication of ID29150A publication Critical patent/ID29150A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/179—Sakei
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDW00200101531A 1999-01-15 2000-01-15 Penggunaan lactobacillus salivarius ID29150A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE990033A IE990033A1 (en) 1999-01-15 1999-01-15 Bifidobacterium longum infantis in the treatment of inflammatory bowel disease
IE990782 1999-09-20

Publications (1)

Publication Number Publication Date
ID29150A true ID29150A (id) 2001-08-02

Family

ID=26320235

Family Applications (2)

Application Number Title Priority Date Filing Date
IDW00200101531A ID29150A (id) 1999-01-15 2000-01-15 Penggunaan lactobacillus salivarius
IDW00200101530A ID30449A (id) 1999-01-15 2000-01-17 Bifidobacterium dalam pengobatan penyakit inflamatori

Family Applications After (1)

Application Number Title Priority Date Filing Date
IDW00200101530A ID30449A (id) 1999-01-15 2000-01-17 Bifidobacterium dalam pengobatan penyakit inflamatori

Country Status (22)

Country Link
US (13) US20020006432A1 (de)
EP (4) EP1141235B1 (de)
JP (2) JP4706016B2 (de)
CN (3) CN101744841B (de)
AT (3) ATE326525T1 (de)
AU (3) AU779405B2 (de)
BR (2) BR0007550A (de)
CA (3) CA2724287A1 (de)
DE (3) DE60035670T2 (de)
DK (2) DK1141235T3 (de)
ES (2) ES2290008T3 (de)
HK (1) HK1044964B (de)
ID (2) ID29150A (de)
IE (1) IE20000033A1 (de)
IL (3) IL144185A0 (de)
MX (2) MXPA01007144A (de)
NO (2) NO327792B1 (de)
NZ (2) NZ530273A (de)
PT (1) PT1141235E (de)
RU (2) RU2279282C2 (de)
TR (2) TR200102058T2 (de)
WO (3) WO2000042168A2 (de)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
EP1212066A4 (de) * 1999-08-09 2004-03-03 Univ Maryland Pro-intestinale reifung und entzündungshemmende wirkung des lactobacillus und der von lactobacillus sekretierten proteinen, kohlenhydraten und lipiden
CN1446103A (zh) * 2000-07-03 2003-10-01 普罗本多有限公司 采用益生菌治疗内毒素血症及相关疾病
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20020054865A1 (en) * 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
CA2424607C (en) 2000-10-06 2013-01-15 Societe Des Produits Nestle S.A. Use of probiotic lactic acid bacteria for balancing the skin's immune system
IT1320772B1 (it) * 2000-11-02 2003-12-10 Proge Farm Srl Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
KR100866199B1 (ko) * 2001-02-01 2008-10-30 가부시끼가이샤 야구르트혼샤 발효유 음식품 중의 비피도박테리움속 세균의 장내 도달도평가방법
EP1373475A2 (de) * 2001-04-02 2004-01-02 Alimentary Health Limited Auf dendritischen zellen basierende immuntherapie
JP4671384B2 (ja) * 2001-05-15 2011-04-13 雪印乳業株式会社 新規乳酸菌株
EP1264893A1 (de) * 2001-06-08 2002-12-11 Teagasc Dairy Products Research Centre Biosynthese von CLA durch Bifidobakterien
PE20030274A1 (es) * 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
JP5116194B2 (ja) * 2001-09-04 2013-01-09 株式会社ヤクルト本社 炎症性腸疾患予防治療剤
US20040241149A1 (en) * 2001-09-05 2004-12-02 Claudio De Simone Use of unmethylatd cpg
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
DE60210497T2 (de) * 2001-12-07 2006-11-23 Morinaga Milk Industry Co. Ltd. Bifidobacterium longum
US6941649B2 (en) * 2002-02-05 2005-09-13 Force10 Networks, Inc. Method of fabricating a high-layer-count backplane
DE10206995B4 (de) * 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
AU2003250503A1 (en) * 2002-06-13 2003-12-31 University College Cork - National University Of Ireland, Cork Probiotic therapies using lactobacillus reuteri
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US7740838B2 (en) * 2002-12-05 2010-06-22 Danisco A/S Bacterial composition and its use
FR2848115B1 (fr) * 2002-12-05 2005-03-25 Rhodia Chimie Sa Composition de bacteries et son utilisation
JP2004189672A (ja) * 2002-12-11 2004-07-08 Gen Corp:Kk 抗下痢症組成物
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
AU2004315890A1 (en) * 2003-12-04 2005-09-01 Burwell, Steve Mr. Methods and compositions for preventing biofilm formations, reducing existing biofilms, and for reducing existing biofilms, and for reducing populations of bacteria
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
WO2005072718A1 (ja) * 2004-01-28 2005-08-11 Kurume University 乳清発酵物を含有する医薬組成物
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2006012536A2 (en) * 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
KR100568036B1 (ko) 2004-08-12 2006-04-07 하남주 장기능 활성화 및 면역기능 강화작용을 하는비피도박테리움 균주 및 이를 함유하는 생균제제
JP2006166829A (ja) * 2004-12-17 2006-06-29 Best Ecology:Kk アイスサプリメント及びその製造方法
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
AU2011205121B2 (en) * 2005-04-08 2012-07-05 Alimentary Health Ltd Method of use of orally administered probiotic bifidobacteria for human beauty benefits
CN101155616A (zh) 2005-04-08 2008-04-02 宝洁公司 用于人类美容有益效果的口服益生菌双歧杆菌的使用方法
US20060228448A1 (en) 2005-04-11 2006-10-12 The Iams Company Pet food compositions comprising two components
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
WO2006130187A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic lactobacilli
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
CN101374425A (zh) * 2005-07-20 2009-02-25 荷兰联合利华有限公司 含有有益细菌的可食用产品
ITMI20051510A1 (it) * 2005-08-02 2007-02-03 Proge Farm Srl Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti
RU2297835C1 (ru) * 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Препарат для лечения неинфекционных воспалительных болезней кишечника
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
CA2647988C (en) * 2006-03-31 2013-05-07 Morinaga Milk Industry Co. Ltd. Interleukin production regulator, pharmaceutical composition, food, and drink containing interleukin production regulator, and production method thereof
WO2007133188A1 (en) * 2006-05-01 2007-11-22 Cobb & Company, Llp Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080118473A1 (en) * 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
US7964238B2 (en) * 2007-01-29 2011-06-21 Guardian Industries Corp. Method of making coated article including ion beam treatment of metal oxide protective film
RU2436581C2 (ru) 2007-02-01 2011-12-20 Дзе Иамс Компани Способ уменьшения воспаления и снижения стресса у млекопитающего
CN101678052A (zh) * 2007-02-22 2010-03-24 于尔根·施赖岑米尔 用于在人中预防、抑制或消除变态反应的益生性革兰氏阳性细菌
ES2381232T3 (es) * 2007-02-28 2012-05-24 Mead Johnson Nutrition Company Procedimiento para el tratamiento o la prevención de la inflamación sistémica
KR20090109131A (ko) * 2007-03-27 2009-10-19 더 프록터 앤드 갬블 캄파니 생균제를 투여하기 위한 방법 및 키트
KR20100016012A (ko) * 2007-03-28 2010-02-12 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
KR20090127180A (ko) 2007-03-28 2009-12-09 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
US8357794B2 (en) * 2007-05-04 2013-01-22 The Procter & Gamble Company and Alimentary Health Limited Exopolysaccharide
EP2522358B1 (de) 2007-06-27 2016-11-09 Laboratorios Ordesa, S.l. Peptide gegen Infektionen mit Rotaviren
JP2009057346A (ja) * 2007-09-03 2009-03-19 Kirin Holdings Co Ltd 免疫バランス調節用組成物
FR2921795B1 (fr) * 2007-10-03 2011-04-29 Gervais Danone Sa Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
EP2225263A1 (de) * 2007-11-26 2010-09-08 Plant Bioscience Limited Neue polypeptide mit endolysinaktivität und anwendungen davon
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
PL2072053T3 (pl) * 2007-12-21 2013-02-28 Gervais Danone Sa Sposób zmniejszania obwodu brzucha przez podawanie bakterii bifidobacterium
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
RU2375960C2 (ru) * 2008-01-28 2009-12-20 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габрического Роспотребнадзора) Способ определения ареактогенного действия препарата пробиотика
EP2110028A1 (de) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum und hippocampale BDNF-Expression
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2293802A4 (de) * 2008-06-25 2011-11-09 Ritter Pharmaceuticals Inc Lactosezusammensetzungen mit reduziertem lactosegehalt
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
CN102089422B (zh) * 2008-07-11 2013-07-17 科.汉森有限公司 新的益生长双歧杆菌
RU2453320C2 (ru) * 2008-08-05 2012-06-20 Виктор Владимирович Чалов Композиция для перорального применения, содержащая непатогенные микроорганизмы, обладающая способностью нормализовать микрофлору кишечника (варианты)
BRPI0919187A2 (pt) * 2008-09-11 2020-11-17 The Iams Company ração para alimento de animal com núcleo à base de proteína e métodos relacionados.
US20100074870A1 (en) * 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 광주과학기술원 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
MX349705B (es) * 2008-11-11 2017-08-09 Alimentary Health Ltd Bifidobacterium longum.
CA2752800C (en) 2009-02-24 2017-12-05 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
US20110027412A1 (en) 2009-07-31 2011-02-03 Kris Eugene Spence Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
ES2664828T3 (es) 2009-08-25 2018-04-23 Nestec S.A. Bifidobacterium longum y trastornos GI funcionales
JP5690270B2 (ja) 2009-09-02 2015-03-25 京都府公立大学法人 乳酸菌由来のｒｎａを有効成分とする組成物
JP2013507394A (ja) * 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
CA2779418C (en) * 2009-11-11 2018-03-20 Alimentary Health Limited Probiotic bifidobacterium strain
PL2823822T3 (pl) * 2009-11-11 2017-09-29 Alimentary Health Limited Szczep Bifidobakterium
EP2528610B1 (de) 2010-01-28 2013-11-13 AB-Biotics S.A. Probiotische Zusammensetzung zur Verwendung bei der Behandlung von Darmentzündung
AU2011209940B2 (en) 2010-02-01 2015-08-20 Ferring Microbiome Inc. Bacteriotherapy for clostridium difficile colitis
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
CN102884174B (zh) * 2010-03-26 2016-08-03 株式会社明治 肠道免疫抑制剂的筛选方法
RU2451741C2 (ru) * 2010-04-26 2012-05-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum АБД-3, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2451740C2 (ru) * 2010-04-26 2012-05-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum АБД-7, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2434058C1 (ru) * 2010-04-26 2011-11-20 Татьяна Александровна Левченко Штамм bifidobacterium longum, используемый для получения бифидосодержащей продукции
WO2011137249A1 (en) * 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
RU2427626C1 (ru) * 2010-05-14 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427636C1 (ru) * 2010-05-14 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427628C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427629C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427630C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
WO2011148219A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
CN102269858A (zh) 2010-06-02 2011-12-07 北京智朗芯光科技有限公司 自动聚焦系统和自动聚焦方法
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
FR2962045B1 (fr) * 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
AU2011286165B2 (en) 2010-08-04 2016-10-20 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112013010783A2 (pt) * 2010-11-11 2016-07-12 Nestec Sa confecções congeladas contendo micro-organismos probióticos
HUE033189T2 (en) 2011-01-31 2017-11-28 Synformulas Gmbh Bifidobacterium bifidum strains for use in gastrointestinal disorders
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
WO2012140636A1 (en) * 2011-04-11 2012-10-18 Alimentary Health Limited A probiotic formulation
RU2460777C1 (ru) * 2011-04-21 2012-09-10 Общество с ограниченной ответственностью "Бифилюкс" Штамм bifidobacterium longum, используемый для получения бифидосодержащей продукции
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101355440B1 (ko) 2011-10-26 2014-02-05 주식회사한국야쿠르트 류마티스 관절염 예방 효능을 갖는 락토바실러스 헬베티쿠스 에이취와이7801 및 이를 유효성분으로 함유하는 제품
CN103131647B (zh) * 2011-11-29 2017-06-27 上海上药信谊药厂有限公司 婴儿双歧杆菌及其制剂
EP3978598B1 (de) 2011-12-01 2024-08-28 The University of Tokyo Von menschen stammende bakterien zur induzierung der proliferation oder akkumulation von regulatorischen t-zellen
WO2013099883A1 (ja) * 2011-12-28 2013-07-04 株式会社山田養蜂場本社 IgA産生促進作用を有する新規乳酸菌及びその用途
EP2828375B1 (de) 2012-01-19 2017-11-22 University College Cork-National University of Ireland, Cork Gaba-erzeugende, aus dem menschlichen magen-darm-trakt stammende kultivierbare bakterie
CN104780932A (zh) 2012-02-29 2015-07-15 伊西康内外科公司 微生物区系的组合物及与其相关的方法
ES2692068T3 (es) 2012-03-29 2018-11-30 Therabiome, Llc Formulaciones para vacunación oral específica a sitio gastrointestinal activas sobre el íleo y el apéndice
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US20150216957A1 (en) 2012-08-20 2015-08-06 Boris Markosian Placental vaccination therapy for cancer
FR2999601B1 (fr) * 2012-12-17 2015-01-30 Urgo Lab Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
JP6464142B2 (ja) 2013-03-14 2019-02-06 セラバイオーム，エルエルシー プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
KR101434220B1 (ko) * 2013-03-26 2014-08-28 삼육대학교산학협력단 다제내성균에 대한 저해 활성을 갖는 신규 유산균
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR102291174B1 (ko) 2013-06-05 2021-08-18 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt), 조성물 및 제조방법
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
GB2535034A (en) 2013-07-21 2016-08-10 Whole Biome Inc Methods and systems for microbiome characterization, monitoring and treatment
CN106414708A (zh) 2014-01-24 2017-02-15 宝洁公司 包含含有微生物的纤维元件的纤维网及其制备方法
CN106414709A (zh) 2014-01-24 2017-02-15 宝洁公司 包含微生物的长丝及其制备方法
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
EP4529950A3 (de) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen im zusammenhang mit mikrobieller behandlung von störungen
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
HRP20180847T1 (hr) 2014-12-23 2018-08-24 4D Pharma Research Limited Pirinski polipeptid i imunološka modulacija
CA2975217C (en) 2015-02-13 2023-08-15 Mars, Incorporated Pet food feeding system
EP3288394A4 (de) 2015-04-28 2019-01-23 Mars, Incorporated Verfahren zur herstellung eines sterilisierten haustier-nassfutterprodukts
KR20180026376A (ko) 2015-05-14 2018-03-12 크레스토보 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
DK3297644T3 (da) 2015-05-22 2022-04-11 Univ Arizona State Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer
EP4541361A3 (de) * 2015-06-01 2025-07-30 The University of Chicago Behandlung von krebs durch manipulation der kommensalen mikroflora
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102342925B1 (ko) 2015-06-09 2021-12-23 리바이오틱스, 인코퍼레이티드 미생물상 복원 치료(ｍｒｔ) 조성물 및 제조 방법
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
PL3650033T3 (pl) 2015-06-15 2022-05-16 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
EP3662917A1 (de) 2015-06-15 2020-06-10 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
US20180280453A1 (en) 2015-08-27 2018-10-04 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
US10233433B2 (en) 2015-08-27 2019-03-19 Alimentary Health Ltd. Bifidobacterium longum
WO2017060698A1 (en) 2015-10-05 2017-04-13 Liam O'mahony Use of akkermansia muciniphila for treating inflammatory conditions
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3209310T3 (pl) 2015-11-20 2018-08-31 4D Pharma Research Limited Kompozycja zawierająca szczepy bakteryjne
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MD3313423T2 (ro) 2016-03-04 2019-10-31 4D Pharma Plc Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale
US10913053B2 (en) * 2016-03-04 2021-02-09 California Institute Of Technology Germanosilicate compositions and methods of preparing the same
RU2659240C2 (ru) * 2016-05-23 2018-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ получения функционального продукта питания для реабилитации онкологических больных
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
IT201600121481A1 (it) * 2016-11-30 2018-05-30 Sintal Dietetics Srl L. salivarius sgl03: attività probiotiche e produzione di proteine antimicrobiche
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107043705A (zh) * 2016-12-30 2017-08-15 大连医科大学 用于建立临床营养菌种资源库的益生菌筛选方法
US11660321B2 (en) * 2017-01-31 2023-05-30 University-Industry Cooperation Group Of Kyung Hee University Method of treatment with lactic acid bacteria
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3064171A1 (en) 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strains
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
HRP20201629T1 (hr) 2017-06-14 2020-12-25 4D Pharma Research Limited Sastavi koji sadrže bakterijski soj roda megasphaera i njihove upotrebe
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6840272B2 (ja) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
AU2018298087A1 (en) 2017-07-05 2020-01-23 Evelo Biosciences, Inc. Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
EP3664823B1 (de) * 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Zusammensetzung zur verwendung bei der vorbeugung oder behandlung von enterokokkalen bluteninfektion
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
RU2665173C1 (ru) * 2017-09-18 2018-08-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ профилактики атопического дерматита у младенцев путем модуляции микробного механизма гистаминообразования
CN111386124A (zh) * 2017-11-01 2020-07-07 表飞鸣制药株式会社 非甾体抗炎药及质子泵抑制剂所诱发的小肠损伤的预防或治疗剂
KR102024883B1 (ko) 2017-11-24 2019-09-24 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
PT3517119T (pt) 2018-01-26 2021-11-30 Probisearch S L U Composição compreendendo nova estirpe de lactobacillus salivarius e método para a prevenção e tratamento de otite e infeções respiratórias superiores
EP3745870B1 (de) * 2018-01-29 2022-11-30 PrecisionBiotics Group Limited Kombinationsprodukt zur prophylaxe und behandlung des reizdarmsyndroms
US11825856B2 (en) * 2018-03-28 2023-11-28 Morinaga Milk Industry Co., Ltd. Composition for preventing or improving functional gastrointestinal disorders, and, pharmaceutical composition, food/beverage composition, and method of preventing or improving functional gastrointestinal disorders using the composition for preventing or improving functional gastrointestinal disorders
RU2670054C1 (ru) * 2018-04-24 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук Штамм бактерий Bifidobacterium bifidum ICIS-310 - продуцент ингибитора провоспалительного цитокина INF-γ
MY202164A (en) 2018-05-09 2024-04-09 Kobiolabs Inc Lactobacillus paracasei strain and use thereof
CN113151036B (zh) * 2018-05-11 2024-08-23 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
BR112020023786A2 (pt) 2018-05-23 2021-03-23 Ko Biolabs, Inc. cepa kbl697 de lactobacillus gasseri e uso da mesma
WO2019227414A1 (zh) * 2018-05-31 2019-12-05 深圳华大生命科学研究院 一种组合物及其应用
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
JP2021532097A (ja) 2018-07-19 2021-11-25 ペンデュラム セラピューティクス， インコーポレイテッド 微生物生着のための方法および組成物
CN109486700A (zh) * 2018-08-31 2019-03-19 石家庄君乐宝乳业有限公司 副干酪乳杆菌n1115预防结肠炎的应用及相应的益生菌粉、应用
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
ES2752798B2 (es) * 2018-10-05 2020-08-12 Consejo Superior Investigacion Cepa de Bifidobacterium longum sub. infantis y uso de la misma
KR102074445B1 (ko) 2018-12-12 2020-02-06 주식회사 비피도 류마티스관절염 개선, 예방 또는 치료를 위한 비피도박테리움 롱검 rapo 균주 및 이를 포함하는 조성물
JP2022541795A (ja) 2019-07-19 2022-09-27 フィンチ セラピューティクス ホールディングス エルエルシー 胃腸障害の治療のための方法および産物
US20220273733A1 (en) * 2019-07-26 2022-09-01 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins
KR102224072B1 (ko) * 2019-08-19 2021-03-10 주식회사 빙그레 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도
CN110547915A (zh) * 2019-08-29 2019-12-10 云南白药清逸堂实业有限公司 应用益生菌的卫生棉制品及其制备方法
CN110452860A (zh) * 2019-09-24 2019-11-15 厦门大学 一种唾液链球菌及其在治疗炎症性肠病药物中的应用
EP4117697A1 (de) 2020-03-13 2023-01-18 PrecisionBiotics Group Limited Bifidobacterium longum
TWI748395B (zh) * 2020-03-31 2021-12-01 豐華生物科技股份有限公司 緩解過敏以及提升運動表現之組合物及其用途
CN113943681B (zh) * 2020-11-12 2023-07-04 江南大学 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌
KR102307603B1 (ko) * 2020-11-13 2021-10-05 주식회사 비피도 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물
CN114317310B (zh) * 2021-03-31 2023-09-22 江苏蓝泽生物科技有限公司 一种抗过敏的婴儿双歧杆菌制剂及其制备方法
CN114558037B (zh) * 2022-02-24 2023-08-15 同济大学 Akk和ls在制备提高认识水平的抗衰老产品中的应用
CN115725456B (zh) * 2022-10-11 2024-06-21 四川大学 一种唾液乳杆菌及其应用
WO2024248549A1 (ko) * 2023-06-01 2024-12-05 재단법인 아산사회복지재단 락토바실러스 살리바리우스 또는 박테로이데스 플레비우스를 포함하는 면역항암제 치료 반응성 및 예후 예측용 바이오마커 및 이를 이용한 면역항암제 치료 반응성 및 예후 예측 방법
CN116574659A (zh) * 2023-06-14 2023-08-11 江南大学 一株可缓解类风湿性关节炎的长双歧杆菌婴儿亚种及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038372B2 (ja) 1975-04-09 1985-08-31 日清製粉株式会社 犬の下痢予防および治療方法
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
US4435389A (en) * 1980-07-07 1984-03-06 Kabushiki Kaisha Yakult Honsha Composition for promoting growth of bifidobacteria
JPS59118712A (ja) * 1982-12-27 1984-07-09 Morinaga Milk Ind Co Ltd 抗腫瘍剤及びその製造法
US4678773A (en) * 1983-08-26 1987-07-07 Chugai Seiyaku Kabushiki Kaisha Antitumor agent
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
JPH0696538B2 (ja) * 1985-12-19 1994-11-30 株式会社アドバンス 抗発癌剤
SU1817285A1 (ru) * 1986-06-05 1996-08-10 Восточно-Сибирский технологический институт Способ приготовления закваски для производства кисломолочных продуктов
JPS63196521A (ja) * 1987-02-10 1988-08-15 Yakult Honsha Co Ltd 腫瘍細胞障害性因子誘起剤
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
DK686187D0 (da) 1987-12-23 1987-12-23 Hansens Chr Bio Syst Veterinaert praeparat
ATE165738T1 (de) 1988-08-02 1998-05-15 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
SE8900546D0 (sv) 1989-02-17 1989-02-17 Bioinvent Int Ab Medel foer inhibering av patogeners adhesion tillvaext och /eller oeverlevnad
NZ232512A (en) 1989-02-21 1993-09-27 Viskase Corp Compositions and firms containing antibacterial agents, methods of treating foodstuffs therewith
JP2932283B2 (ja) * 1989-07-14 1999-08-09 雪印乳業株式会社 ビフィズス菌を含有する醗酵乳の製造方法
DE4033996A1 (de) * 1990-10-25 1992-04-30 Karl Heinz Hoelzel Enzymatisches stoffwechselprodukt zur symbioselenkung und verfahren zu seiner herstellung
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
ATE153063T1 (de) * 1992-07-06 1997-05-15 Nestle Sa Milchbakterien
RU2048517C1 (ru) * 1992-09-24 1995-11-20 Институт микробиологии Штамм бактерий bifidobacterium longum, используемый для приготовления бактериальных препаратов и кисломолочных продуктов
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
JPH0782158A (ja) * 1993-09-16 1995-03-28 Yakult Honsha Co Ltd 抗腫瘍剤
JP3623977B2 (ja) * 1993-10-29 2005-02-23 明治乳業株式会社 潰瘍性大腸炎治療剤
JPH07265064A (ja) * 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
DE69530910D1 (de) * 1994-07-15 2003-07-03 Taiyo Kagaku Co Medizinische zusammensetzungen enthaltend ein sialinsäurederivat
JP2780154B2 (ja) * 1995-02-17 1998-07-30 株式会社ヤクルト本社 ヨーグルト
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
RU2091075C1 (ru) * 1995-06-28 1997-09-27 Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Комплексный бактериальный препарат для лечения и профилактики желудочно-кишечных заболеваний животных
JP4021951B2 (ja) * 1996-03-01 2007-12-12 わかもと製薬株式会社 乳酸菌を有効成分とする抗胃炎剤、抗潰瘍剤および醗酵食品
JPH09241179A (ja) * 1996-03-01 1997-09-16 Meiji Seika Kaisha Ltd ビフィドバクテリウム属菌由来の水溶性免疫賦活物質およびその精製法
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
TW357191B (en) * 1996-06-04 1999-05-01 Food Industry Development Res Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
IT1288119B1 (it) 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
NZ337505A (en) * 1997-02-11 2001-07-27 Univ College Cork Nat Univ Ie Isolated antimicrobial agents from Lactobacillus salivarius
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
RU2109054C1 (ru) 1997-04-01 1998-04-20 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Консорциум бифидобактерий bifidobacterium bifidum 791, b. longum b 379 m, b. breve 79-119, b. infantis 73-15, b. adolescentis г 7513 для приготовления кисломолочных, неферментированных пищевых продуктов и бактерийных препаратов
CN1178703A (zh) * 1997-08-06 1998-04-15 北京东方百信生物技术有限公司 幼儿胃肠安制剂及其生产工艺
EP0904784A1 (de) 1997-09-22 1999-03-31 N.V. Nutricia Probiotisches Ernährungspräparat
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
FI980782A7 (fi) 1998-04-03 1999-10-04 Timo Korhonen Epiteelisoluihin sitoutuva proteiinialue ja sitä koodaava DNA-sekvenssi
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
JP4203981B2 (ja) 1998-05-29 2009-01-07 エンタープライズ・アイルランド 生菌チーズの製造法
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AUPQ415899A0 (en) 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
ATE419331T1 (de) 2000-08-25 2009-01-15 Wakamoto Pharma Co Ltd L. salivarius-stamm enthaltende probiotische produkte
US6618973B2 (en) * 2001-05-15 2003-09-16 Ned H. Nelson Banner holder

Also Published As

Publication number Publication date
US20060292133A1 (en) 2006-12-28
WO2000041707A3 (en) 2001-09-27
US20100112003A1 (en) 2010-05-06
BRPI0007481B8 (pt) 2021-07-06
AU3071700A (en) 2000-08-01
ES2265331T3 (es) 2007-02-16
US20030170217A1 (en) 2003-09-11
CN1245994C (zh) 2006-03-22
US20080057109A1 (en) 2008-03-06
RU2001119046A (ru) 2003-06-20
IL144185A (en) 2009-05-04
US20050214272A1 (en) 2005-09-29
ATE326012T1 (de) 2006-06-15
ATE326525T1 (de) 2006-06-15
TR200102059T2 (tr) 2002-02-21
ES2290008T3 (es) 2008-02-16
DE60027866D1 (de) 2006-06-14
MXPA01007152A (es) 2003-04-02
TR200102058T2 (tr) 2001-12-21
AU3071500A (en) 2000-08-01
CN100552016C (zh) 2009-10-21
ATE367820T1 (de) 2007-08-15
US20080311080A1 (en) 2008-12-18
AU3071600A (en) 2000-08-01
BRPI0007481B1 (pt) 2015-12-15
US20070141039A1 (en) 2007-06-21
RU2279282C2 (ru) 2006-07-10
BR0007550A (pt) 2001-10-30
IE20000033A1 (en) 2000-08-09
NO20013467L (no) 2001-09-14
JP2002534113A (ja) 2002-10-15
JP2004502633A (ja) 2004-01-29
IL144185A0 (en) 2002-05-23
WO2000041707A2 (en) 2000-07-20
DE60035670T2 (de) 2008-04-30
US20050084482A1 (en) 2005-04-21
CA2724287A1 (en) 2000-07-20
EP1145001A2 (de) 2001-10-17
EP1143985A2 (de) 2001-10-17
DK1141235T3 (da) 2006-09-18
WO2000042168A3 (en) 2000-11-16
NZ530273A (en) 2005-04-29
EP1145001B1 (de) 2006-05-10
US20020006432A1 (en) 2002-01-17
WO2000042429A3 (en) 2001-10-11
NO20013429L (no) 2001-08-27
MXPA01007144A (es) 2002-04-24
EP1143985A3 (de) 2002-08-28
JP4706016B2 (ja) 2011-06-22
US7195906B2 (en) 2007-03-27
CA2359334A1 (en) 2000-07-20
NZ529353A (en) 2005-06-24
NO327792B1 (no) 2009-09-28
CN1338940A (zh) 2002-03-06
HK1044964B (zh) 2010-01-15
DE60028003T2 (de) 2007-04-12
HK1044964A1 (zh) 2002-11-08
PT1141235E (pt) 2006-10-31
EP1688481A1 (de) 2006-08-09
ID30449A (id) 2001-12-06
CN1342196A (zh) 2002-03-27
EP1143985B1 (de) 2007-07-25
DE60028003D1 (de) 2006-06-22
WO2000042168A2 (en) 2000-07-20
CN101744841B (zh) 2013-05-15
CN101744841A (zh) 2010-06-23
CA2360243A1 (en) 2000-07-20
NO20013429D0 (no) 2001-07-10
EP1141235A2 (de) 2001-10-10
DK1143985T3 (da) 2007-11-19
CA2359334C (en) 2011-03-22
IL144184A0 (en) 2002-05-23
US20030215467A1 (en) 2003-11-20
RU2308483C2 (ru) 2007-10-20
US20030166257A1 (en) 2003-09-04
US20050074441A1 (en) 2005-04-07
AU779405B2 (en) 2005-01-20
DE60035670D1 (de) 2007-09-06
US20060002908A1 (en) 2006-01-05
WO2000042429A2 (en) 2000-07-20
EP1141235B1 (de) 2006-05-17
BRPI0007481A (pt) 2002-04-09
NO20013467D0 (no) 2001-07-12

Similar Documents

Publication Publication Date Title
ID29150A (id) Penggunaan lactobacillus salivarius
BR0211438A (pt) Cepas de lactobacillus casei próbióticas
BR0211442A (pt) Cepas de bifidobacterium probióticas
MXPA04000808A (es) Cepas probioticas de lactobacillus salivarius.
ATE534396T1 (de) Probiotische mikroorganismen zur verbesserung der muskulären funktion
WO2008117266A3 (en) Probiotic bifidobacterium strains
IL245956A0 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
BRPI0417805A (pt) lactobacilli probióticos caninos
EA200101262A1 (ru) Диетическая или фармацевтическая композиция для применения в целях профилактики или лечения гипероксалурии
BR9608284A (pt) Composição farmacêutica compreendendo lactobacillus plantarum e arginina
RU2003112420A (ru) Биопрепарат лечебно-профилактического действия при эндометритах животных
AU2002344953A1 (en) Strain of micro-organism lactobacillus fermentum me-3 as novel anti-microbial and antioxidative probiotic